Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum

NCT03010072 is registered in ClinicalTrials.gov with Prim. Priv. Doz. Dr. Daniel Cejka as lead sponsor.

NCT NCT03010072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03010072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum
Lead sponsor
Prim. Priv. Doz. Dr. Daniel Cejka
Phase
Phase 2
Overall status
Completed
Start date
June 9, 2017
Completion date
May 10, 2019
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endstage renal disease